Mikro-RNA: Rolle bei der Immunregulation nach allogener hämatopoetischer Stammzelltransplantation

Zusammenfassung

Immunregulation nach allogener hämatopoetischer Stammzelltransplantation (allo-HSZT) beschreibt das empfindliche Gleichgewicht zwischen dem erwünschten Transplantat-gegen-Leukämie Effekt (GvL) und der Vermeidung der unerwünschten Transplantat-gegen-Wirt-Reaktion (GvHD). Bei verschiedenen entzündlichen und malignen Erkrankungen wurde bereits über eine Rolle von Mikro-RNA (miRNA) berichtet. Insbesondere bei Autoimmunerkrankungen, Allergien und GvHD findet man häufig eine dysregulierte Expression verschiedener miRNA. Der Artikel soll eine Übersicht über aktuelle Erkenntnisse zur Rolle von miRNA bei der Immunregulation nach allo-HSZT darstellen und einen Ausblick auf neue potenzielle diagnostische und therapeutische Möglichkeiten wie beispielsweise die Nutzung von miRNA im Serum als Biomarker oder die Modifikation einer Immunantwort durch miRNA Mimetics geben.

Abstract

Immunoregulation following allogeneic hematopoietic stem cell transplantation (allo-HSCT) involves the delicate balance between the desirable graft-versus-leukemia (GvL) effect and the prevention of the undesirable graft-versus-host disease (GvHD). Emerging evidence has shown that microRNAs (miRNAs) play a role in the pathogenesis of different inflammatory and malignant diseases. Especially in autoimmune diseases, allergy and GvHD numerous dysregulated miRNAs have been identified. In this review, we provide an overview of current knowledge about the role of miRNAs in the immunoregulation after allo-HSCT. Moreover, we give an outlook on potential new diagnostic and therapeutic approaches, including the use of miRNAs as clinical biomarkers and the manipulation of immune responses using miRNA mimetics.

Schlüsselwörter

Mikro-RNA - Immunregulation - Transplantat gegen Wirt Reaktion - Graft-versus-host disease (GvHD) - allogene hämatopoetische Stammzelltransplantation

Key words

microRNA - Immunoregulation - Graft-versus-host disease (GvHD) - allogeneic hematopoietic stem cell transplantation

• Literatur

• 1 Allegra A, Alonci A, Campo S et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Intern J Oncol 2012; 41: 1897-1912
• 2 Androulidaki A, Iliopoulos D, Arranz A et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009; 31: 220-231
• 3 Atarod S, Dickinson AM. MicroRNAs: The Missing Link in the Biology of Graft-Versus-Host Disease?. Front Immunol 2013; 4: 420
• 4 Baltimore D, Boldin MP, O'Connell RM et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 8: 839-845
• 5 Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nature Rev Immuno 2012; 12: 443-458
• 6 Boldin MP, Taganov KD, Rao DS et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208: 1189-1201
• 7 Bousquet M, Quelen C, Rosati R et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205: 2499-2506
• 8 Brunstein CG, Miller JS, Cao Q et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061-1070
• 9 Chong MM, Rasmussen JP, Rudensky AY et al. The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med 2008; 205: 2005-2017
• 10 Cobb BS, Nesterova TB, Thompson E et al. T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. J Exp Med 2005; 201: 1367-1373
• 11 Cohen JL, Trenado A, Vasey D et al. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406
• 12 Du C, Liu C, Kang J et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nature Immunol 2009; 10: 1252-1259
• 13 Hechinger AK, Maas K, Dürr C et al. Inhibition of protein geranylgeranylation and farnesylation protects against GvHD via effects on CD4 effector T cells. Haematologica 2013; 98: 31-40
• 14 Hoffmann P, Ermann J, Edinger M et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399
• 15 Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693-706
• 16 Jankovic D, Ganesan J, Bscheider M et al. The Nlrp3-inflammasome regulates acute graft-versus-host disease. J Exp Med 2013; 210: 1899-1910
• 17 Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-1694
• 18 Junker A. Pathophysiology of translational regulation by microRNAs in multiple sclerosis. FEBS letters 2011; 585: 3738-3746
• 19 Keller A, Leidinger P, Lange J et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009; 4: e7440
• 20 Koralov SB, Muljo SA, Galler GR et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008; 132: 860-874
• 21 Kurowska-Stolarska M, Alivernini S, Ballantine LE et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A 2011; 108: 11193-11198
• 22 Lagos-Quintana M, Rauhut R, Lendeckel W et al. Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858
• 23 Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854
• 24 Lee Y, Kim M, Han J et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-4060
• 25 Leonhardt F, Grundmann S, Behe M et al. Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100. Blood 2013; 121: 3307-3318
• 26 Leonhardt F, Zirlik K, Buchner M et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia 2012; 26: 1617-1629
• 27 Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20
• 28 Li J, Wan Y, Guo Q et al. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arth Res Ther 2010; 12: R81
• 29 Li QJ, Chau J, Ebert PJ et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007; 129: 147-161
• 30 Lim LP, Lau NC, Garrett-Engele P et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773
• 31 Liston A, Lu LF, O'Carroll D et al. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med 2008; 205: 1993-2004
• 32 Muljo SA, Ansel KM, Kanellopoulou C et al. Aberrant T cell differentiation in the absence of Dicer. J Exp Med 2005; 202: 261-269
• 33 Murata K, Yoshitomi H, Tanida S et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arth Res Ther 2010; 12: R86
• 34 Niimoto T, Nakasa T, Ishikawa M et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskel Dis 2010; 11: 209
• 35 O'Connell RM, Chaudhuri AA, Rao DS et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A 2009; 106: 7113-7118
• 36 O'Connell RM, Kahn D, Gibson WS et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010; 33: 607-619
• 37 O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nature Rev Immunol 2011; 11: 163-175
• 38 Otaegui D, Baranzini SE, Armananzas R et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 2009; 4: e6309
• 39 Penack O, Henke E, Suh D et al. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst 2010; 102: 894-908
• 40 Ponomarev ED, Veremeyko T, Barteneva N et al. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nature Med 2011; 17: 64-70
• 41 Qiu Z, Dai Y. Roadmap of miR-122-related clinical application from bench to bedside. Expert Opin Investig Drugs 2014; 3: 347-355
• 42 Ranganathan P, Heaphy CE, Costinean S et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012; 119: 4786-4797
• 43 Reinhart BJ, Slack FJ, Basson M et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403: 901-906
• 44 Rodriguez A, Griffiths-Jones S, Ashurst JL et al. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14: 1902-1910
• 45 Rodriguez A, Vigorito E, Clare S et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316: 608-611
• 46 Schwab L, Goroncy L, Palaniyandi S et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage. Nat Med 2014; in press
• 47 Sheedy FJ, Palsson-McDermott E, Hennessy EJ et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nature Immunol 2010; 11: 141-147
• 48 Stanczyk J, Pedrioli DM, Brentano F et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arth Rheum 2008; 58: 1001-1009
• 49 Stittrich AB, Haftmann C, Sgouroudis E et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nature Immunol 2010; 11: 1057-1062
• 50 Taganov KD, Boldin MP, Chang KJ et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006; 103: 12481-12486
• 51 Thai TH, Calado DP, Casola S et al. Regulation of the germinal center response by microRNA-155. Science 2007; 316: 604-608
• 52 Thompson LF, Tsukamoto H, Chernogorova P et al. A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs. tumor effect. Oncoimmunology 2013; 2: e22107
• 53 Tili E, Michaille JJ, Cimino A et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179: 5082-5089
• 54 Velu CS, Chaubey A, Phelan JD et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest 2014; 124: 222-236
• 55 Wang L, Romero M, Ratajczak P et al. Increased apoptosis is linked to severe acute GVHD in patients with Fanconi anemia. Bone Marrow Transplant 2013; 48: 849-853
• 56 Wilhelm K, Ganesan J, Müller T et al. Graft-versus-host disease enhanced by extracellular adenosine triphosphate activating P2X7R. Nature Med 2010; 12: 1434-1438
• 57 Xiao B, Wang Y, Li W et al. Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. Blood 2013; 122: 3365-3375
• 58 Xie LN, Zhou F, Liu XM et al. Serum microRNA155 is increased in patients with acute graft-versus-host disease. Clin Transplant 2014; 28: 314-323
• 59 Yang L, Boldin MP, Yu Y et al. miR-146a controls the resolution of T cell responses in mice. J Exp Med 2012; 209: 1655-1670